Johnson & Johnson (NYSE:JNJ) Stock Price Down 0.9%

Shares of Johnson & Johnson (NYSE:JNJ) were down 0.9% during trading on Thursday . The stock traded as low as $165.82 and last traded at $165.89. Approximately 952,112 shares changed hands during trading, a decline of 87% from the average daily volume of 7,232,066 shares. The stock had previously closed at $167.36.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Down 0.4 %

The company has a market capitalization of $395.61 billion, a P/E ratio of 10.25, a PEG ratio of 2.73 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a 50 day moving average price of $157.57 and a 200 day moving average price of $153.83.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.80 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. GUNN & Co INVESTMENT MANAGEMENT INC. grew its holdings in Johnson & Johnson by 1,194.9% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after buying an additional 218,949 shares in the last quarter. Gilbert & Cook Inc. grew its holdings in Johnson & Johnson by 3.3% during the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after buying an additional 288 shares in the last quarter. 9258 Wealth Management LLC grew its holdings in Johnson & Johnson by 2.1% during the 4th quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock valued at $3,454,000 after buying an additional 443 shares in the last quarter. Sheets Smith Wealth Management grew its holdings in Johnson & Johnson by 11.6% during the 4th quarter. Sheets Smith Wealth Management now owns 13,821 shares of the company’s stock valued at $2,166,000 after buying an additional 1,432 shares in the last quarter. Finally, Channing Capital Management LLC grew its holdings in Johnson & Johnson by 5.3% during the 4th quarter. Channing Capital Management LLC now owns 53,142 shares of the company’s stock valued at $8,329,000 after buying an additional 2,692 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.